Outcome of Board Meeting

Ref: 16/SE/LC/2026-27 Date: June 26, 2026 Scrip Code BSE: 544122 NSE: ENTERO ISIN: INE010601016 Head, Listing Compliance Department Head, Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Dalal Street, Exchange Plaza, Plot No. C/1. G Block, Mumbai - 400 001 Bandra -Kurla Complex, Bandra (East), Mumbai- 400 051 Dear Sir/Madam, Subject: Outcome of Board Meeting held on June 26, 2026 Reference: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“LODR”) Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“LODR”), we wish to inform you that the Board of Directors of the Company, at its meeting held today, considered and approved following: 1. Based on the recommendations of the Nomination and Remuneration Committee, the Board has approved allotment of 1,475 (One Thousand Four Hundred and Seventy-Five) Equity Shares of Rs. 10/- (Rupees Ten) each of the Company, to the eligible employee of the Company, upon exercise of the Options vested under the Entero Employee Stock Option Plan 2023. The details as required under the Regulation 10(c) SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 are enclosed as Annexure A. 2. In reference to our earlier intimation dated May 25, 2026, Ref. No.: 06/SE/LC/2026-27, it is further informed that based on the recommendation of the Nomination and Remuneration Committee, the Board has approved the revised tenure of reappointment of the Independent Directors to facilitate an effective succession planning process and ensure a smoother transition in the composition of the Board. Accordingly, the Board has approved the revised tenure for the re-appointment of Mr. Rajesh Shashikant Dalal (DIN: 03504969) and Ms. Sandhya Gadkari Sharma (DIN: 02005378) as Non-Executive Independent Directors of the Company, subject to the approval of the shareholders at the ensuing Annual General Meeting. The tenure of Mr. Sujesh Vasudevan (DIN: 08240092) Non-Executive Independent Director remains unchanged. The details required to be furnished in compliance with Regulation 30 read with Part A of Schedule III of SEBI Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026, as amended, are enclosed as Annexure-B. The above information will also be available on the website of the Company at www.enterohealthcare.com The Board Meeting commenced at 01:00 p.m. (IST) and concluded at 02.45 p.m. (IST). You are requested to take the same on record. Yours faithfully, For Entero Healthcare Solutions Limited Sanu Kapoor Vice President- General Counsel, Company Secretary & Compliance Officer Encl: as above Annexure – A Disclosures pursuant to Regulation 10 (c) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021: Sr. Particulars Disclosure No. Entero Employee Stock Option Plan 2023 1. Company Name and Address of Entero Healthcare Solutions Limited Registered Office Plot No. I-35, Building -B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Faridabad, Haryana, India, 121003. 2. Name of the Stock Exchanges on which BSE Limited and the Company’s shares are listed National Stock Exchange of India Limited (NSE) 3. Filing date of the statement referred in BSE: 20/09/2024 regulation 10(b) of the SEBI SBEB NSE: 20/09/2024 Regulations, with Stock Exchange 4. Filing Number, if any BSE: 212075 NSE: 44198 5. Title of the Scheme pursuant to which Entero Employee Stock Option Plan 2023 shares are issued 6. Kind of security to be listed Equity shares 7. Par value of the shares Rs. 10/- 8. Date of issue of shares June 26, 2026 9. Number of shares issued 1,475 10. Share Certificate No., if applicable N.A. 11. Distinctive number of shares, if 4,35,21,598 to 4,35,23,072 applicable 12. ISIN Number of the shares if issued in INE010601016 Demat 13. Exercise price per share Rs. 804 per equity share 14. Premium per share Rs. 794/- per equity share 15. Total Issued shares after this issue 4,35,23,072 16. Total Issued share capital after this issue Rs. 43,52,30,720 17. Details of any lock-in on the shares The shares issued upon exercise shall be freely transferable and shall not be subject to any lock - in period restriction after such issue except as required under the Applicable Laws. 18. Date of expiry of lock-in Not Applicable 19. Whether shares are identical in all All equity shares of the Company allotted respects to existing shares if not, when pursuant to exercise of stock options shall rank will they become identical? pari-passu with the existing equity shares of the Company 20. Details of listing fees, if payable Not Applicable Annexure-B Details in terms of Regulation 30 read with Para A of Part A of Schedule III of SEBI Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026: Particulars Mr. Rajesh Shashikant Dalal Ms. Sandhya Gadkari Sharma Reason for change viz. Reappointment for 2nd term of 4 Reappointment for 2nd term of 4 appointment, re-appointment (Four) consecutive years. (Four) consecutive years. resignation, removal, death or otherwise Date of appointment/cessation (as Date of Re-Appointment - Date of Re-Appointment - applicable) and term of August 25, 2026. August 25, 2026. appointment Term of Re-appointment - 2nd Term of Re-appointment - 2nd term of 4 (Four) consecutive term of 4 (Four) consecutive years commencing from August years commencing from August 25, 2026, to August 24, 2030. 25, 2026, to August 24, 2030. Brief Profile (in case of Mr. Rajesh Shashikant Dalal is a Ms. Sandhya Gadkari Sharma appointment) healthcare leader and has 35 has over Four decades of plus years of experience. He has experience in Banking and been Managing Director of Investment. She obtained her Johnson & Johnson India. Later bachelor’s degree of he took Asia wide responsibility Commerce from the University for M & A for Johnson & Johnson. of Bombay and a master’s in After leaving Johnson & Johnson, management studies from he has worked closely with the University of Bombay. Private Equity firms helping them Previously, she was associated evaluate healthcare with Mahindra and Mahindra opportunities and investing in Limited and ICICI Bank Limited them. He has also helped blue chip international companies like Philips Netherlands, Intuitive Surgicals USA, Alltech China etc. in formulating their India strategies. Rajesh is a mechanical Engineer from IIT Madras and MBA from Jamanalal Bajaj Institute Bombay. Disclosure of relationships Not Applicable between Directors (in case of appointment of a Director) Information as required pursuant to Not debarred from holding the office of Director by virtue of any BSE Circular with ref. no. SEBI order or any other such authority. LIST/COMP/14/2018-19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/ 24, both dated 20 June 2018